DprE1-IN-15 

DprE1-IN-15 is a covalent Mycobacterium tuberculosis essential cell wall enzyme DprE1 inhibitor with an IC₅₀ of 0.073 μM. DprE1-IN-15 forms an irreversible covalent adduct with its target enzyme. DprE1-IN-15 shows inhibitory effects against multiple Mycobacterium tuberculosis^[1].

DprE1-IN-15 (Compound 11c) (30 min) potently inhibits purified Mycobacterium tuberculosis DprE1 with an IC₅₀ of 0.073 μM via covalent adduct formation^[1].
DprE1-IN-15 (7 days) potently inhibits growth of drug-sensitive Mycobacterium tuberculosis H₃₇Rv and extensively drug-resistant TB strains 13946 and 14862, with an MIC of <0.002 μM for all tested strains^[1].
DprE1-IN-15 (0.26-64 μg/mL; 48 h) exhibits no significant cytotoxicity against Vero or HepG2 cells, with an IC₅₀ of >100 μM for both cell lines^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

DprE1-IN-15 (Compound 11c) (5-50 mg/kg; p.o., i.v.; single dose) exhibits an oral bioavailability of 31.9% in male CD-1 mice, with favorable systemic exposure following both oral and intravenous administration^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

539.36

C₂₀H₂₁F₅N₄O₃Se

O=C1N=C(N2CCN(CC3CCC(F)(F)CC3)CC2)[Se]C4=C([N+]([O-])=O)C=C(C(F)(F)F)C=C14

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Liu Y, et al. Discovery of Potent Benzoselenazinone-Based DprE1 Inhibitors: A Novel Selenium-Containing Scaffold with Superior Anti-TB Activity and Pharmacokinetic Properties. J Med Chem. 2026;69(9):10579-10593.